ArticleArchives of osteoporosis2025
Persistence of romosozumab vs. teriparatide in Japanese older adults aged ≥ 75 years with osteoporosis: a population-based cohort study.
Article in Archives of osteoporosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discontinuation risk for osteoporosis therapy rises in older adults. In a study of 8,677 Japanese patients aged ≥ 75 years, 365-day discontinuation was 41.4% with romosozumab and 70.9% with teriparatide. This suggests that the less frequent, once-a-month dosing schedule of romosozumab may improve treatment adherence in this population. PURPOSE: To compare one-year treatment persistence between romosozumab and teriparatide in Japanese patients aged 75-99 years with osteoporosis.
methodsWe performed an active comparator new-user cohort study using a Japanese health insurance claims database (April 2018-March 2023). Eligible patients initiated romosozumab or any teriparatide formulation between March 2019 and March 2022. We used inverse probability weighting to balance measured baseline covariates. The study outcome was treatment discontinuation within 365 days. Cumulative incidence functions accounted for the competing risk of death. Subgroup analyses were performed by teriparatide formulation (daily, weekly, twice-weekly), by sex, and by age group (75-84 vs. 85-99 years).
resultsAmong 8,677 eligible patients (romosozumab, n = 1,869; teriparatide, n = 6,808; mean age 86.1 years; 12.6% men), baseline covariates were well-balanced after weighting. At 365 days, the weighted cumulative incidence (risk) of discontinuation was 41.4% (95% CI, 38.4 to 44.4) for romosozumab versus 70.9% (95% CI, 69.8 to 72.0) for teriparatide (risk ratio, 0.58; 95% CI, 0.54 to 0.63). Twice-weekly teriparatide showed the highest persistence among teriparatide formulations but remained inferior to romosozumab. Across both treatment arms, women had lower discontinuation risk than men, and patients aged 75-84 years had lower risk than those aged 85-99 years.
conclusionsRomosozumab demonstrated higher one-year persistence than any teriparatide formulation in Japanese patients aged ≥ 75 years. Its monthly administration may lessen the adherence barriers posed by more frequent teriparatide injections. This finding may aid treatment decision-making for older patients with osteoporosis.
Indexed as
Identifiers
41400755What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.